Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer.

Wang, Chongkai; Chevalier, Dawnyel; Saluja, Janelle; Sandhu, Jaideep; Lau, Cecilia; Fakih, Marwan

Wang, Chongkai; Chevalier, Dawnyel; Saluja, Janelle; Sandhu, Jaideep; Lau, Cecilia; Fakih, Marwan.

Afiliación

Wang C; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Chevalier D; Department of Nursing, City of Hope National Medical Center, Duarte, California, USA.
Saluja J; Department of Nursing, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Sandhu J; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Lau C; Department of Pharmacy Services, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Fakih M; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Oncologist ; 25(8): e1188-e1194, 2020 08.

Article en En | MEDLINE | ID: mdl-32406541

Asunto(s)

ADN Tumoral Circulante; Neoplasias Colorrectales; Anticuerpos Monoclonales Humanizados; ADN Tumoral Circulante/genética; Neoplasias Colorrectales/tratamiento farmacológico; Neoplasias Colorrectales/genética; Humanos; Repeticiones de Microsatélite; Nivolumab/uso terapéutico; Compuestos de Fenilurea/uso terapéutico; Piridinas

Palabras clave

Colorectal cancer; Microsatellite stability; Nivolumab; Regorafenib

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / ADN Tumoral Circulante Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google